JPRN-UMIN000003102已完成未知
Phase I-II Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for Non-Small Cell Lung Cancer - Phase I-II Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for Non-Small Cell Lung Cancer
Department of Thoracic Medical Oncoligy CancernInstitute Hospital Japanese foundation for cancer reseach0 个研究点目标入组 43 人开始时间: 2010年1月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Clinically significant serious disease
研究者
相似试验
已完成
1 期
Phase I/II study of Irinotecan and Erlotinib in patients for EGFR mutation negative previously treated non-small-cell lung cancer.JPRN-UMIN000005181Osaka Univ. Hospital Respiratory Medicine27
已完成
1 期
Phase I Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for EGFR Mutations Non-Small Cell Lung CancerJPRN-UMIN000005873Hamamatsu University School of Medicine, First Department of Surgery1
已完成
1 期
Phase I/II Study of Irinotecan and Gemcitabine in Pediatric, adolescent and Young Adult Patients with Relapsed or Refractory Solid TumorsRelapse/refractory pediatric/AYA solid tumorJPRN-UMIN000020144Group for "combination chemotherapies for refractory Adolescent and Young Adult solid tumors "10
招募中
1 期
A phaseI/II study of Erlotinib/Carboplatin/Pemetrexed/Bevacizumab in chemotherapy-naive patients with EGFR mutation positive advanced non-squamous non-small-cell lung canceron-Small-Cell Lung CancerJPRN-UMIN000013202Kansai Medical University Hirakata Hospital35
进行中（未招募）
不适用
A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapy - phase II erlotinib-sorafenib in advanced NSCLCAdvanced non small cell lung cancerEUCTR2007-004625-14-NLVU University Medical Centre48